Cancer Letters
Volume 205, Issue 2 , Pages 189-195 , 18 March 2004

PACAP expression and distribution in human breast cancer and healthy tissue

  • M.Olga Garcı́a-Fernández

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain
    • ,
  • Guillermo Bodega

      Affiliations

    • Department of Cell Biology and Genetics, University of Alcalá, Alcalá de Henares, Spain
    • ,
  • Antonio Ruı́z-Villaespesa

      Affiliations

    • Department of Pathology, Prı́ncipe de Asturias Hospital, Alcalá de Henares, Spain
    • ,
  • Joaquı́n Cortés

      Affiliations

    • Department of Medical Specialities, University of Alcalá, Alcalá de Henares, Spain
    • Department of Obstetrics and Gynecology, Prı́ncipe de Asturias Hospital, Alcalá de Henares, Spain
    • ,
  • Juan C. Prieto

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34-91-885-4527; fax: +34-91-885-4585
    • ,
  • Marı́a J. Carmena

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain

Received 19 March 2003 ,Revised 9 September 2003 ,Accepted 3 October 2003.

References 

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J. Clin. 1999;8–31
  2. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J. Natl Cancer Inst. 1993;85:892–897
  3. Polyak K. On the birth of breast cancer. Biochim. Biophys. Acta. 2001;1552:1–13
  4. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol. 1978;5:428–432
  5. Volpi A, de Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, et al.  Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res. Treat. 2000;63:181–192
  6. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 2000;26:91–102
  7. Wolman SR, Heppner GH, Wolman E. New directions in breast cancer research. Fed. Am. Soc. Exp. Biol. J. 1997;11:535–543
  8. Vaudry D, González BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 2000;52:269–324
  9. Sherwood NM, Kruecki SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 2000;21:619–670
  10. Hosoya M, Kimura C, Ogi K, Ohkubo S, Miyamoto Y, Kugoh H, et al.  Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochim. Biophys. Acta. 1992;1129:199–206
  11. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front. Neuroendocrinol. 1995;16:53–88
  12. Skakkebaek M, Hannibal J, Fahrenkrug J. Pituitary adenylate cyclase activating polypeptide (PACAP) in the rat mammary gland. Cell Tissue Res. 1999;298:153–159
  13. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60:3105–3112
  14. Yanaihara H, Vigh S, Kozicz T, Somogyvari-Vigh A, Arimura A. Immunohistochemical demonstration of the intracellular localization of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat testis using the stamp preparation. Regul. Pept. 1998;78:83–88
  15. Garcı́a-Fernández MO, Bodega G, Solano RM, Ruı́z-Villaespesa A, Sánchez-Chapado M, Carmena MJ, et al. Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tisúes. Regul. Pept. 2002;110:9–15
  16. Vandekerckhove J, Weber K. Mammalian cytoplasmatic actins are the products of at least two genes and differ in primary structure in at least 25 identified positions from skeletal muscle actins. Proc. Natl Acad. Sci. USA. 1978;75:1106–1110
  17. Eriksson M, Lindh B, Uvnäs-Moberg K, Hökfelt T. Distribution and origin of peptide-containing fibers in the rat and human mammary gland. Neuroscience. 1996;70:227–245
  18. Mack D, Hacker GW, Hauser-Kronberger C, Frick J, Dietze O. Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. Eur. J. Cancer. 1997;33:317–318
  19. Coffey DS. Similarities of prostate and breast cancer: evolution, diet and estrogens. Urology. 2001;57(Suppl. 4A):31–38
  20. Li M, Nakayama K, Shuto Y, Somogyvari-Vigh A, Arimura A. Testis-specific prohormone convertase PC4 processes the precursor of pituitary adenylate cyclase-activating polypeptide (PACAP). Peptides. 1998;19:259–268
  21. Seidah NG, Chretien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 1999;848:45–62
  22. Bergeron F, Leduc R, Day R. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J. Mol. Endocrinol. 2000;24:1–22
  23. Wilson HE, White A. Prohormones: their clinical relevance. Trends Endocrinol. Metab. 1998;9:396–402
  24. Vincze E, Kántor O, Kiss A, Gonda G, Gombás P, Kiss J, et al.  Pituitary adenylate cyclase activating polypeptide (PACAP) is present in human and cat gastric glands. Peptides. 1999;20:937–941

PII: S0304-3835(03)00691-8

doi: 10.1016/j.canlet.2003.10.008

Cancer Letters
Volume 205, Issue 2 , Pages 189-195 , 18 March 2004

Article Tools

* Image Usage & Resolution